Recurrence Prevention with SGLT2i after Ablation in Patients with EF-Preserved AF

Recurrence prEvention with SGLT2i and Therapy after ablation in Outcomes for Rhythm control in EF-preserved AF: RESTORE-AF Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011882

Enrollment

462

Registered

2026-04-20

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : This is a prospective, randomized, open-label interventional study designed to evaluate the effect of dapagliflozin administered before and after catheter ablation in patients with atrial fibri

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with a history of heart failure with preserved ejection fraction or NT-proBNP =660 pg/mL according to the HFA-PEFF criteria 2.Patients aged 19 years or older with atrial fibrillation 3.Patients eligible for catheter ablation according to current clinical guidelines 4.Patients without clinically significant structural heart disease (e.g., severe mitral regurgitation) 5.Patients without contraindications to anticoagulation therapy

Exclusion criteria

Exclusion criteria: 1.Atrial fibrillation associated with severe congenital or hemodynamically significant structural heart disease 2.Contraindications to general anesthesia or sedation for the procedure 3.History of prior cardiac surgery such as Maze surgery or coronary artery bypass grafting 4.History of one or more prior catheter ablations for atrial fibrillation 5.Active internal bleeding 6.Contraindications to anticoagulation therapy or antiarrhythmic drugs 7.Valvular atrial fibrillation (mitral stenosis > grade 2, mechanical valve, or prior mitral valve repair) 8.Severe concomitant illness 9.Expected survival of less than 1 year 10.Drug or alcohol addiction 11.Pregnant or breastfeeding women 12.Any other condition judged by the investigator to make the patient unsuitable for the study

Design outcomes

Primary

Measure	Time frame
Clinical recurrence of atrial fibrillation within 1 year after catheter ablation, excluding the first 3-month blanking period	—

Secondary

Measure	Time frame
Atrial fibrillation burden assessed by 7-day single-lead wearable ECG;Adverse event rate after dapagliflozin treatment;Patient-reported quality of life assessed by AFEQT;Changes in echocardiographic parameters before and after ablation (EF, left atrial anteroposterior diameter)	—

Countries

Korea, Republic of

Contacts

Public ContactJunbeom Park

Ewha Womans University Medical Center

newriser@naver.com+82-2-2650-5826

Outcome results